Proteasome Inhibitors
1 drugsAbout Proteasome
The proteasome is a large protein complex responsible for degrading unneeded or damaged proteins through proteolysis. This function is critical for cellular regulation, making it a therapeutic target.
Inhibiting the proteasome disrupts protein degradation, leading to cell death, especially in rapidly dividing cancer cells. Currently, there is no genetic evidence directly linking the proteasome to specific diseases.
The proteasome is targeted by one FDA-approved drug, NINLARO (Takeda), a small molecule used in oncology. NINLARO was first approved in 2015.
Top Proteasome Drugs
Takeda is the only company with an approved drug targeting the proteasome.
Low competition indicates a potential market opportunity, but also a higher risk due to lack of validation by multiple players.
Proteasome Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Proteasome, using small molecule modality.
The lack of modality diversity suggests an opportunity to explore alternative approaches like antibodies or PROTACs.
Proteasome Clinical Trials 113 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Proteasome. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 47 | 25 | 13 | 9 | 66% |
| Phase 2 | 50 | 27 | 13 | 10 | 68% |
| Phase 3 | 10 | 8 | 2 | 0 | 80% |
| Phase 4 | 6 | 3 | 2 | 1 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Proteasome Drug Approval Timeline (2015 - 2015)
The first and only drug, NINLARO, was approved in 2015.
The lack of recent approvals suggests potential saturation or challenges in developing new proteasome inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 58 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Proteasome. A trial counts if an approved drug acting on Proteasome is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.